September 19 2011 Biotechnology Firm ImmuneWorks Supports Pulmonary Fibrosis Week by Increasing National Recruitment Efforts to Enroll Idiopathic Pulmonary Fibrosis (IPF) Patients in Clinical Trial

INDIANAPOLIS, IN, Sep 19, 2011 (MARKETWIRE via COMTEX) — Biotechnology firm,
ImmuneWorks, is ramping up efforts to support National Pulmonary Fibrosis (PF)
Awareness Week (September 18-24). IPF is one of the most fatal, yet publicly
unrecognized, diseases claiming more and more lives every year. This week
ImmuneWorks plans to open four additional clinical trial sites to test its
experimental treatment for idiopathic pulmonary fibrosis (IPF). The company is
increasing national recruitment efforts to enroll IPF patients in its
FDA-approved research study.

IPF is a devastating lung disease that is progressive and generally fatal. An
estimated 128,000 persons in the United States suffer from IPF, with 48,000 new
persons diagnosed annually and 40,000 patients dying from the disease each year
(source:Coalition for Pulmonary Fibrosis). The number of deaths annually is the
same as breast cancer and greater than other cancers such as multiple myeloma.
Currently no FDA-approved medicines exist for IPF in the United States.

Read the entire article at:

http://www.marketwatch.com/story/biotechnology-firm-immuneworks-supports-pulmonary-fibrosis-week-by-increasing-national-recruitment-efforts-to-enroll-idiopathic-pulmonary-fibrosis-ipf-patients-in-clinical-trial-2011-09-19?reflink=MW_news_stmp

or go to www.ipftoday.com for more news.